Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 1;178(11):1516-1525.
doi: 10.1001/jamainternmed.2018.4273.

Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease

Zachary Bouck  1 , Graham C Mecredy  2 , Noah M Ivers  1   2   3   4 , Moumita Barua  5   6   7   8 , Danielle Martin  1   3   4 , Peter C Austin  2   3   9 , Joshua Tepper  3   4   10 , R Sacha Bhatia  1   2   3
Affiliations

Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease

Zachary Bouck et al. JAMA Intern Med. .

Abstract

Importance: International nephrology societies advise against nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease (CKD); however, recent studies have not investigated the frequency or associations of use in these patients.

Objectives: To estimate the frequency of and variation in prescription NSAID use among high-risk patients, to identify characteristics associated with prescription NSAID use, and to investigate whether use is associated with short-term, safety-related outcomes.

Design, setting, and participants: In this retrospective cohort study, administrative claims databases were linked to create a cohort of primary care visits for a musculoskeletal disorder involving patients 65 years and older with a history of hypertension, heart failure, or CKD between April 1, 2012, and March 31, 2016, in Ontario, Canada.

Exposure: Prescription NSAID use was defined as at least 1 patient-level Ontario Drug Benefit claim for a prescription NSAID dispensing within 7 days after a visit.

Main outcomes and measures: Multiple cardiovascular and renal safety-related outcomes were observed between 8 and 37 days after each visit, including cardiac complications (any emergency department visit or hospitalization for cardiovascular disease), renal complications (any hospitalization for hyperkalemia, acute kidney injury, or dialysis), and death.

Results: The study identified 2 415 291 musculoskeletal-related primary care visits by 814 049 older adults (mean [SD] age, 75.3 [4.0] years; 61.1% female) with hypertension, heart failure, or CKD, of which 224 825 (9.3%) were followed by prescription NSAID use. The median physician-level prescribing rate was 11.0% (interquartile range, 6.7%-16.7%) among 7365 primary care physicians. Within a sample of 35 552 matched patient pairs, each consisting of an exposed and nonexposed patient matched on the logit of their propensity score for prescription NSAID use (exposure), the study found similar rates of cardiac complications (288 [0.8%] vs 279 [0.8%]), renal complications (34 [0.1%] vs 33 [0.1%]), and death (27 [0.1%] vs 30 [0.1%]). For cardiovascular and renal-safety related outcomes, there was no difference between exposed patients (308 [0.9%]) and nonexposed patients (300 [0.8%]) (absolute risk reduction, 0.0003; 95% CI, -0.001 to 0.002; P = .74).

Conclusions and relevance: While prescription NSAID use in primary care was frequent among high-risk patients, with widespread physician-level variation, use was not associated with increased risk of short-term, safety-related outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Cohort Creation
CKD indicates chronic kidney disease; LHIN, Local Health Integrated Network; and MSK, musculoskeletal.
Figure 2.
Figure 2.. Prescription Nonsteroidal Anti-inflammatory Drug (NSAID) Use Over Time (by Quarter) in Ontario, Fiscal Year 2012-2013 to Fiscal Year 2015-2016
The horizontal hatched line represents the mean rate.
Figure 3.
Figure 3.. Variation in Prescription Nonsteroidal Anti-inflammatory Drug (NSAID) Use by 7536 Primary Care Physicians in Ontario, Fiscal Year 2012-2013 to Fiscal Year 2015-2016
See this image and copyright information in PMC

Comment in

References

    1. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004-2008: a retrospective patient record review. J Pain Res. 2010;3:131-135. - PMC - PubMed
    1. Hasselström J, Liu-Palmgren J, Rasjö-Wrååk G. Prevalence of pain in general practice. Eur J Pain. 2002;6(5):375-385. doi:10.1016/S1090-3801(02)00025-3 - DOI - PubMed
    1. Lawry GV II, Schuldt SS, Kreiter CD, Densen P, Albanese MA. Teaching a screening musculoskeletal examination: a randomized, controlled trial of different instructional methods. Acad Med. 1999;74(2):199-201. doi:10.1097/00001888-199902000-00020 - DOI - PubMed
    1. Jin J. Nonsteroidal anti-inflammatory drugs. JAMA. 2015;314(10):1084. doi:10.1001/jama.2015.9936 - DOI - PubMed
    1. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000. doi:10.1161/ATVBAHA.110.207449 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances